PPARs in Clinical Experimental Medicine after 35 Years of Worldwide Scientific Investigations and Medical Experiments

Biomolecules. 2024 Jul 1;14(7):786. doi: 10.3390/biom14070786.

Abstract

This year marks the 35th anniversary of Professor Walter Wahli's discovery of the PPARs (Peroxisome Proliferator-Activated Receptors) family of nuclear hormone receptors. To mark the occasion, the editors of the scientific periodical Biomolecules decided to publish a special issue in his honor. This paper summarizes what is known about PPARs and shows how trends have changed and how research on PPARs has evolved. The article also highlights the importance of PPARs and what role they play in various diseases and ailments. The paper is in a mixed form; essentially it is a review article, but it has been enriched with the results of our experiments. The selection of works was subjective, as there are more than 200,000 publications in the PubMed database alone. First, all papers done on an animal model were discarded at the outset. What remained was still far too large to describe directly. Therefore, only papers that were outstanding, groundbreaking, or simply interesting were described and briefly commented on.

Keywords: PPARs; clinical application; experimental therapy; peroxisome proliferator-activated receptor.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomedical Research / history
  • History, 20th Century
  • Humans
  • Peroxisome Proliferator-Activated Receptors* / metabolism

Substances

  • Peroxisome Proliferator-Activated Receptors

Grants and funding

This research received no external funding.